FALBERG KATHRYN E 4

What Happened Kathryn E. Falberg, a director of Nuvation Bio, was granted a derivative award covering 123,397 shares on May 21, 2026. The Form 4 reports the acquisition price as $0 (an award/derivative transaction), so there was no cash outlay shown in the filing. The award is described in the filing as an option-like grant that vests based on continued service.

Key Details

• Transaction date: 2026-05-21; transaction type: Award/derivative (code A); reported price: $0 per share.
• Shares subject to the award: 123,397 shares.
• Vesting note: 100% of the shares subject to the option vest on the earlier of (i) the one‑year anniversary of the grant date or (ii) the next shareholder annual meeting, subject to continuous service. (Footnote from filing.)
• Shares owned after the transaction: Not specified in the provided filing.
• Filing date: 2026-05-26 (appears to be filed 5 days after the transaction date; Form 4s are generally due within two business days).

Context This was a compensation-related award to a director, not an open-market purchase or sale. Such grants are commonly used to compensate and retain directors and do not necessarily signal immediate buying or selling intent. Because this is a derivative/option-style award with vesting conditions, the shares are not immediately freely tradable.